Editorial| Volume 289, P181-183, October 2019

The challenges of measuring Lp(a): A fight against Hydra?

  • Florian Kronenberg
    Corresponding author. Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstr, 41, A-6020, Innsbruck, Austria.
    Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstr, 41, A-6020, Innsbruck, Austria
    Search for articles by this author
  • Sotirios Tsimikas
    Corresponding author. Division of Cardiovascular Diseases, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0682, USA.
    Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiovascular Diseases, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, USA
    Search for articles by this author
      The Hydra of Lerna is a serpentine water monster in Greek mythology. The Hydra possessed many heads that had an enormous regenerative capacity: whenever a head was cut off, the Hydra would regrow two heads. Thus, it was not easy for the ancient hero Herakles to win against this constantly regenerating problem.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kronenberg F.
        • Utermann G.
        Lipoprotein(a) - resurrected by genetics.
        J. Intern. Med. 2013; 273: 6-30
        • Sandholzer C.
        • Saha N.
        • Kark J.D.
        • et al.
        Apo(a) isoforms predict risk for coronary heart disease: a study in six populations.
        Arterioscler. Thromb. 1992; 12: 1214-1226
        • Saleheen D.
        • Haycock P.C.
        • Zhao W.
        • et al.
        Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.
        Lancet Diabetes Endocrinol. 2017; 5: 524-533
        • Kamstrup P.R.
        • Tybjaerg-Hansen A.
        • Steffensen R.
        • Nordestgaard B.G.
        Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
        J. Am. Med. Assoc. 2009; 301: 2331-2339
        • Albers J.J.
        • Hazzard W.R.
        Immunochemical quantification of human plasma Lp(a) lipoprotein.
        Lipids. 1974; 9: 15-26
        • Tsimikas S.
        • Fazio S.
        • Ferdinand K.C.
        • et al.
        NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.
        J. Am. Coll. Cardiol. 2018; 71: 177-192
        • Yeang C.
        • Clopton P.C.
        • Tsimikas S.
        Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: implications for clinical practice interpretation of Lp(a)-mediated risk.
        J. Clin. Lipidol. 2016; 10: 1389-1396
        • Lamon-Fava S.
        • Marcovina S.M.
        • Albers J.J.
        • et al.
        Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the framingham offspring study.
        J. Lipid Res. 2011; 52: 1181-1187
        • Scharnagl H.
        • Stojakovic T.
        • Dieplinger B.
        • et al.
        Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays.
        Atherosclerosis. 2019; : 206-213
        • Utermann G.
        The mysteries of lipoprotein(a).
        Science. 1989; 246: 904-910
        • Marcovina S.M.
        • Albers J.J.
        • Gabel B.
        • Koschinsky M.L.
        • Gaur V.P.
        Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a).
        Clin. Chem. 1995; 41: 246-255
        • Coassin S.
        • Schoenherr S.
        • Weissensteiner H.
        • et al.
        A comprehensive map of single base polymorphisms in the hypervariable LPA Kringle IV-2 copy number variation region.
        J. Lipid Res. 2019; 60: 186-199
        • Lassman M.E.
        • McLaughlin T.M.
        • Zhou H.
        • et al.
        Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry.
        Rapid Commun. Mass Spectrom. 2014; 28: 1101-1106
        • Tsimikas S.
        • Fazio S.
        • Viney N.J.
        • et al.
        Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
        J. Clin. Lipidol. 2018; 12: 1313-1323
        • Perombelon Y.F.N.
        • Soutar A.K.
        • Knight B.L.
        Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles.
        J. Clin. Investig. 1994; 93: 1481-1492
        • Coassin S.
        • Erhart G.
        • Weissensteiner H.
        • et al.
        A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction.
        Eur. Heart J. 2017; 38: 1823-1831
        • Kronenberg F.
        Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region.
        Clin. Res. Cardiol. Suppl. 2019; 14: 5-12
        • Zheng K.H.
        • Tsimikas S.
        • Pawade T.
        • et al.
        Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis.
        J. Am. Coll. Cardiol. 2019; 73: 2150-2162
        • Viney N.J.
        • van Capelleveen J.C.
        • Geary R.S.
        • et al.
        Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
        Lancet. 2016; 388: 2239-2253
      1. Kronenberg F. Therapeutic lowering of lipoprotein(a): how much is enough?, Atherosclerosis: doi: 10.1016/j.atherosclerosis.2019.07.003 (in press).

      Linked Article